China Inflammatory Bowel Disease (IBD) Market

China Inflammatory Bowel Disease (IBD) Market Size, Share & Trends Analysis Report by Disease Type (Ulcerative Colitis and Crohn’s Disease), By Diagnostics (Blood & Stool Tests, Endoscopies, Ultrasound, and X-Ray), By Therapeutics (Surgery and Anti- Inflammatory Drug Administration) and Forecast 2019-2025
    Update Available - Forecast 2024-2030   

Published: Jul 2022 | Report Code: OMR2021222 | Category : Pharmaceuticals | Delivery Format: /

China IBD market is estimated to grow significantly at a CAGR of around 5.8% during the forecast period. With the huge number of smokers in China, rapid industrialization, and changing lifestyle, the rate of IBD prevalence is estimated to increase in recent decade. These factors further raises the risk of IBD and contribute in the rising demand of diagnosis and treatment solutions thus creating significant market in the country. According to the World Bank, China had reported 49.2% of total males, smokes regularly in 2014, while the figure was 48.7% and 48.4% in 2015 and 2016 respectively. Smoking causes an adverse effect on small and large intestines, which as a result increasing the prevalence rate of IBD that further contribute to the growth of the market.

China IBD market is segmented on the basis of disease type, diagnostics, and therapeutics. China IBD market is segmented on the basis of disease type into ulcerative colitis and Crohn’s disease. Crohn’s disease segment is estimated to dominate the market. The growth of the segment is attributed to the comparatively higher incidence of Crohn’s disease than ulcerative colitis. On the basis of diagnostics, the market segmented into blood and stool, endoscopies, ultrasound, and X-rays. Endoscopy is a conventional diagnostic method that is widely being used for the diagnosis of IBD and having a considerable share in the market. The therapeutics segment is further segmented into anti-inflammatory drugs and surgery. There is a range of anti-inflammatory drugs used for the treatment of IBD, such as immunosuppressants (methotrexate, ciclosporin, and azathioprine), steroids and biological drugs. These are usually the first step in the treatment of IBD. 

The companies which are contributing to the growth of the China IBD market include AbbVie Inc., Allergan, PLC, Boehringer Ingelheim International GmbH, Eli Lilly and Co., Daiichi Sankyo Co. Ltd., Mercator Pharmaceutical Solutions  Johnson & Johnson Services Inc., Pfizer Inc., Sanofi S.A., Takeda pharmaceutical Co., Ltd.  and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, and technological advancements to stay competitive in the market. 

Research Methodology

The market study of China IBD market is incorporated by extensive primary and secondary research conducted by the research team.  Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

Market Segmentation

  1. China IBD Market Research and Analysis by Disease Type
  2. China IBD Market Research and Analysis by Diagnostics
  3. China IBD Market Research and Analysis by Therapeutics

The Report Covers

  • Comprehensive research methodology of the China IBD market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the China IBD market.
  • Insights about market determinants which are stimulating the China IBD market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

1. Report Summary

1.1. Research Methods and Tools

1.2. Market Breakdown

1.2.1. By Segments

2. Market Overview and Insights

2.1. Scope of the Report

2.2. Analyst Insight & Current Market Trends

2.2.1. Key Findings

2.2.2. Recommendations

2.2.3. Conclusion

2.3. Rules & Regulations

3. Competitive Landscape

3.1. Company Share Analysis

3.2. Key Strategy Analysis

3.3. Key Company Analysis

3.3.1. Overview 

3.3.2. Financial Analysis 

3.3.3. SWOT Analysis

3.3.4. Recent Developments

4. Market Determinants

4.1. Motivators

4.2. Restraints

4.3. Opportunities

5. Market Segmentation

5.1. China IBD Market by Disease Type

5.1.1. Ulcerative Colitis 

5.1.2. Crohn’s Disease

5.2. China IBD Market by Diagnostics

5.2.1. Blood and Stool Tests 

5.2.2. Endoscopies, 

5.2.3. Ultrasound 

5.2.4. X-Ray 

5.3. China IBD Market by Therapeutics

5.3.1. Surgery

5.3.2. Anti- Inflammatory Drug Administration

5.3.2.1. Steroids

5.3.2.2. Immunosuppressant

5.3.2.3. Biological Drugs

5.3.2.4. Amino salicylates

5.3.2.5. Others

6. Company Profiles

6.1. AbbVie Inc.

6.2. Allergan, PLC

6.3. Boehringer Ingelheim International GmbH

6.4. Daiichi Sankyo Co. Ltd.

6.5. Eli Lilly and Co.

6.6. Johnson & Johnson Services Inc.

6.7. Mercator Pharmaceutical Solutions 

6.8. Pfizer Inc.

6.9. Sanofi S.A.

6.10. Takeda pharmaceutical Co., Ltd. 

1. CHINA IBD MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2018-2025 ($ MILLION)

2. CHINA IBD MARKET RESEARCH AND ANALYSIS BY DIAGNOSTICS, 2018-2025 ($ MILLION)

3. CHINA IBD MARKET RESEARCH AND ANALYSIS BY THERAPEUTICS, 2018-2025 ($ MILLION)

1. CHINA IBD MARKET SHARE BY DISEASE TYPE, 2018 VS 2025 (%)

2. CHINA IBD MARKET SHARE BY DIAGNOSTICS, 2018 VS 2025 (%)

3. CHINA IBD MARKET SHARE BY THERAPEUTICS, 2018 VS 2025 (%)